Immunoglobulin Light Chain (AL) Amyloidosis Clinical Trials in Westmead, New South Wales

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion